PL2402005T3 - Formulacje nalbufiny o przedłużonym uwalnianiu - Google Patents

Formulacje nalbufiny o przedłużonym uwalnianiu

Info

Publication number
PL2402005T3
PL2402005T3 PL11178912T PL11178912T PL2402005T3 PL 2402005 T3 PL2402005 T3 PL 2402005T3 PL 11178912 T PL11178912 T PL 11178912T PL 11178912 T PL11178912 T PL 11178912T PL 2402005 T3 PL2402005 T3 PL 2402005T3
Authority
PL
Poland
Prior art keywords
nalbuphine
sustained release
release formulations
formulations
sustained
Prior art date
Application number
PL11178912T
Other languages
English (en)
Inventor
Anand Baichwal
Thomas Sciascia
Donald Diehl
Brian Vogler
Original Assignee
Endo Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc. filed Critical Endo Pharmaceuticals Inc.
Publication of PL2402005T3 publication Critical patent/PL2402005T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11178912T 2005-08-24 2006-08-24 Formulacje nalbufiny o przedłużonym uwalnianiu PL2402005T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71077205P 2005-08-24 2005-08-24
US77246606P 2006-02-10 2006-02-10
PCT/US2006/033011 WO2007025005A2 (en) 2005-08-24 2006-08-24 Sustained release formulations of nalbuphine
EP11178912.9A EP2402005B1 (en) 2005-08-24 2006-08-24 Sustained release formulations of nalbuphine
EP06789964.1A EP1931315B1 (en) 2005-08-24 2006-08-24 Sustained release formulations of nalbuphine

Publications (1)

Publication Number Publication Date
PL2402005T3 true PL2402005T3 (pl) 2021-11-22

Family

ID=37772363

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06789964T PL1931315T3 (pl) 2005-08-24 2006-08-24 Formulacje o przedłużonym uwalnianiu nalbufiny
PL11178912T PL2402005T3 (pl) 2005-08-24 2006-08-24 Formulacje nalbufiny o przedłużonym uwalnianiu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06789964T PL1931315T3 (pl) 2005-08-24 2006-08-24 Formulacje o przedłużonym uwalnianiu nalbufiny

Country Status (10)

Country Link
US (2) US8771732B2 (pl)
EP (2) EP2402005B1 (pl)
JP (1) JP2009506059A (pl)
CA (2) CA2620224C (pl)
DK (2) DK2402005T3 (pl)
ES (2) ES2441766T3 (pl)
HU (1) HUE053838T2 (pl)
PL (2) PL1931315T3 (pl)
PT (2) PT1931315E (pl)
WO (1) WO2007025005A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EA014739B1 (ru) * 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
RU2008113439A (ru) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
JP5453280B2 (ja) * 2007-10-16 2014-03-26 ラボファーム インコーポレイテッド アセトアミノフェンおよびトラマドールを持続的に放出するための二層組成物
WO2009076764A1 (en) * 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
EP2326316A1 (en) * 2008-08-07 2011-06-01 Avantor Performance Materials, Inc. Sustained release compositions comprising gums and sugar alcohols
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9289423B2 (en) 2011-04-29 2016-03-22 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
ES2984559T3 (es) * 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
US20150359789A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2017100971A (ja) * 2015-11-30 2017-06-08 株式会社ファンケル 錠剤
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
US20180125840A1 (en) * 2016-10-25 2018-05-10 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4282215A (en) 1980-06-17 1981-08-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
US4404210A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and ibuprofen
US4407804A (en) 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and indomethacin
US4407805A (en) 1982-06-30 1983-10-04 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and zomepirac
US4404211A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and flurbiprofen
US4404208A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and tiflamizole
US4404209A (en) 1982-06-30 1983-09-13 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and sulindac
US4402962A (en) 1982-06-30 1983-09-06 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
EP0615756B1 (en) 1993-03-15 2001-06-27 National Science Council Nalbuphine esters and long-acting pharmaceutical compositions containing them
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA02002193A (es) 1999-08-31 2002-09-30 Gr Nenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
DE60036874T2 (de) 1999-09-02 2008-06-26 Nostrum Pharmaceuticals Inc. Pellet formulierung mit gesteuerter freisetzung
BR0013719A (pt) 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Dosagem oral de liberaçâo controlada, apropriada para administração oral
KR100463496B1 (ko) * 1999-09-30 2005-01-06 펜웨스트 파머슈티칼즈 컴파니 고가용성 약물용 서방성 메트리스 시스템
EP1149836B1 (en) 2000-04-27 2003-02-26 Oliver Yoa-Pu Hu Polynalbuphine derivatives
EP1292307A2 (en) 2000-06-09 2003-03-19 The Regents of The University of California Method of treating pain using nalbuphine and opioid antagonists
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
CN100356907C (zh) 2001-06-08 2007-12-26 恩德制药公司 利用丙烯酸酯聚合物的控释剂型和其制备方法
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
CA2541371C (en) 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
EP1584335A3 (en) 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain

Also Published As

Publication number Publication date
EP1931315B1 (en) 2013-10-16
US9186330B2 (en) 2015-11-17
DK2402005T3 (da) 2021-03-15
HUE053838T2 (hu) 2021-07-28
CA2620224C (en) 2015-11-24
DK1931315T3 (da) 2014-01-20
WO2007025005A2 (en) 2007-03-01
ES2441766T3 (es) 2014-02-06
WO2007025005A3 (en) 2007-12-21
US20070048376A1 (en) 2007-03-01
EP2402005B1 (en) 2020-12-16
EP1931315A2 (en) 2008-06-18
PT2402005T (pt) 2021-04-14
US20140315937A1 (en) 2014-10-23
CA2620224A1 (en) 2007-03-01
EP2402005A1 (en) 2012-01-04
US8771732B2 (en) 2014-07-08
PL1931315T3 (pl) 2014-09-30
PT1931315E (pt) 2014-01-03
CA2881739A1 (en) 2007-03-01
JP2009506059A (ja) 2009-02-12
CA2881739C (en) 2018-01-02
ES2862573T3 (es) 2021-10-07

Similar Documents

Publication Publication Date Title
HUE053838T2 (hu) Nyújtott felszabadulású nabulfin-készítmények
IL216401A0 (en) Sustained release of antinfectives
IL184460A0 (en) Sustained release pharmaeutical formulations
IL185800A0 (en) Controlled release formulations of octreotide
IL184822A0 (en) Extended release formulation of levetiracetam
GB0406819D0 (en) Controlled release compositions
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
IL179991A0 (en) Modified release formulation of memantine
GB0505909D0 (en) Formulations
IL188964A0 (en) Sustained drug release composition
IL178596A0 (en) Sustained release formulations
EP1765385A4 (en) IMPORTS COMPOSITION WITH DELAYED RELEASE
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
SI1732548T2 (sl) Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem
IL190865A0 (en) Formulations of quinolinones
ZA200705011B (en) Formulations of substituted benzoxazoles
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1951693A4 (en) SOLID FORMULATIONS
GB0505569D0 (en) Formulations
IL178383A0 (en) Delayed release formulations of 6-mercaptopurine
IL177328A0 (en) Controlled release formulations
IL198169A0 (en) Robust sustained release formulations of oxymorphone
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
ZA200803213B (en) Formulations of quinolinones